CO5560581A2 - Vacuna de epitopo de celula t beta-amiloide analogo - Google Patents
Vacuna de epitopo de celula t beta-amiloide analogoInfo
- Publication number
- CO5560581A2 CO5560581A2 CO04015504A CO04015504A CO5560581A2 CO 5560581 A2 CO5560581 A2 CO 5560581A2 CO 04015504 A CO04015504 A CO 04015504A CO 04015504 A CO04015504 A CO 04015504A CO 5560581 A2 CO5560581 A2 CO 5560581A2
- Authority
- CO
- Colombia
- Prior art keywords
- app
- analog
- animal
- epitope
- foreign
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 9
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 9
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 9
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 9
- 210000000987 immune system Anatomy 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000003831 deregulation Effects 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
Abstract
1.- Un método para la desregulación in vivo de proteína precursora de amiloide (APP) o beta amiloide (Aß) en un animal, incluyendo un ser humano, el método comprende efectuar la presentación al sistema inmune del animal de una cantidad inmunogénicamente efectiva de al menos un análogo de APP o Aß que incorpora en la misma molécula una fracción sustancial de epítopos de célula B de APP y/o Aß, de modo que el análogo reacciona en el mismo grado que lo hace la APP o Aß con suero policlonal dirigido contra APP o Aß, y al menos un epítopo auxiliar T ajeno (epítopo TH) de modo que la inmunización del animal con el análogo induce la producción de anticuerpos contra APP o Aß autóloga del animal, donde el análogo a) es un poliamino ácido que contiene al menos un epítopo TH ajeno y una secuencia de APP o Aß perturbada, de modo que el análogo no incluye ninguna subsecuencia de la SEQ ID NO: 2 que se una productivamente a moléculas MHC de la clase II iniciando una respuesta de célula T; y/o b) es un conjugado que comprende una estructura de polihidroxipolímero a la cual se acopla por separado un poliaminoácido como se definió en a); y/o c) un conjugado que comprende una estructura de polihidroxipolímero a la cual se acopla por separado a) al menos un epítopo TH ajeno y 2) una secuencia perturbada de APP o Aß como se definió en b).2.- El método de conformidad con la reivindicación 1, donde - es introducida al menos una primera porción la cual efectúa la dirección del análogo a una célula presentadora de antígenos (APC) o un linfocito B, y/o - es introducida al menos una segunda porción la cual estimula el sistema inmune, y/o- es introducida al menos una tercera porción la cual optimiza la presentación del análogo al sistema inmune.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101231 | 2001-08-20 | ||
| US33754301P | 2001-10-22 | 2001-10-22 | |
| US37302702P | 2002-04-16 | 2002-04-16 | |
| DKPA200200558 | 2002-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5560581A2 true CO5560581A2 (es) | 2005-09-30 |
Family
ID=32870659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04015504A CO5560581A2 (es) | 2001-08-20 | 2004-02-23 | Vacuna de epitopo de celula t beta-amiloide analogo |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20030157117A1 (es) |
| EP (3) | EP1685847A1 (es) |
| JP (2) | JP2004538332A (es) |
| KR (3) | KR101057488B1 (es) |
| CN (1) | CN101675992B (es) |
| AR (1) | AR036270A1 (es) |
| AT (1) | ATE334698T1 (es) |
| AU (3) | AU2002325199B2 (es) |
| BR (1) | BR0212047A (es) |
| CA (1) | CA2457140C (es) |
| CO (1) | CO5560581A2 (es) |
| CY (1) | CY1105737T1 (es) |
| DE (1) | DE60213615T3 (es) |
| DK (1) | DK1420815T3 (es) |
| EA (2) | EA007533B1 (es) |
| ES (1) | ES2269749T5 (es) |
| HK (1) | HK1064934A1 (es) |
| HR (2) | HRP20040218A2 (es) |
| HU (1) | HUP0400669A3 (es) |
| IL (2) | IL159964A0 (es) |
| IS (1) | IS7133A (es) |
| ME (1) | MEP43208A (es) |
| MX (1) | MXPA04001467A (es) |
| MY (1) | MY144532A (es) |
| NZ (2) | NZ547224A (es) |
| PL (1) | PL215125B1 (es) |
| PT (1) | PT1420815E (es) |
| RS (1) | RS51699B (es) |
| SI (1) | SI1420815T1 (es) |
| WO (1) | WO2003015812A2 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20022748A3 (cs) * | 2000-02-21 | 2004-03-17 | Pharmexa A/S | Nová metoda regulace obsahu amyloidu |
| EE200200444A (et) * | 2000-02-21 | 2003-12-15 | Pharmexa A/S | Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks |
| US7320793B2 (en) | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| US20080014194A1 (en) * | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US8506959B2 (en) * | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8697082B2 (en) * | 2002-11-01 | 2014-04-15 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| KR100546066B1 (ko) * | 2003-03-21 | 2006-01-26 | 한국생명공학연구원 | 베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물 |
| US7358331B2 (en) * | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| US7807171B2 (en) | 2003-07-25 | 2010-10-05 | Ac Immune Sa | Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| WO2005042575A2 (en) * | 2003-10-30 | 2005-05-12 | Pharmexa A/S | Method for down-regulation of vegf |
| US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
| JP2007522119A (ja) * | 2004-01-28 | 2007-08-09 | キュリックス エーピーエス | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート |
| KR100639397B1 (ko) * | 2004-03-18 | 2006-10-26 | (주)에스제이바이오메드 | 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물 |
| GB0424563D0 (en) * | 2004-11-05 | 2004-12-08 | Novartis Ag | Organic compounds |
| KR20080005260A (ko) * | 2005-05-05 | 2008-01-10 | 머크 앤드 캄파니 인코포레이티드 | 알츠하이머 질환의 예방 및 치료를 위한 펩티드 접합체조성물 및 방법 |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
| KR20080103560A (ko) * | 2006-02-22 | 2008-11-27 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신 |
| WO2008070284A2 (en) | 2006-10-16 | 2008-06-12 | Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute | Amyloid beta peptides and methods of uses thereof |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| DK3067066T3 (da) * | 2007-02-23 | 2019-05-20 | Prothena Biosciences Ltd | Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom |
| WO2008104386A2 (en) | 2007-02-27 | 2008-09-04 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US7618944B2 (en) * | 2007-03-01 | 2009-11-17 | Intezyne Technologies, Inc. | Encapsulated amyloid-beta peptides |
| WO2008124646A2 (en) * | 2007-04-06 | 2008-10-16 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Use of amyloid proteins as vaccine scaffolds |
| ES2655868T3 (es) | 2007-04-20 | 2018-02-22 | The Chemo-Sero-Therapeutic Research Institute | Método para aumentar la respuesta inmunitaria con un péptido |
| CN102089000A (zh) * | 2008-07-08 | 2011-06-08 | 默沙东公司 | 用于治疗阿尔茨海默病的疫苗 |
| JP5474807B2 (ja) * | 2008-10-16 | 2014-04-16 | 一般財団法人化学及血清療法研究所 | 改変アミロイドβペプチド |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
| CN103189050B (zh) | 2010-10-26 | 2017-09-29 | Ac免疫有限公司 | 包含通过疏水部分修饰的肽的基于脂质体的构建体 |
| US20120328605A1 (en) * | 2010-10-27 | 2012-12-27 | Daniel Larocque | Compositions and uses |
| WO2014031697A2 (en) * | 2012-08-21 | 2014-02-27 | The Institute Of Molecular Medicine | COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN |
| WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| WO2015036646A1 (es) * | 2013-09-13 | 2015-03-19 | Fundación Pública Andaluza Progreso Y Salud | Combinaciones de proteínas agregantes y chaperonas moleculares para el tratamiento de proteinopatías o enfermedades conformacionales |
| US10087226B2 (en) | 2014-03-11 | 2018-10-02 | Universite D'aix-Marseille | Chimeric peptide that interacts with cell membrane gangliosides |
| CA2971288A1 (en) * | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
| JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
| CN104880441B (zh) * | 2015-05-14 | 2017-12-22 | 上海皓拓生物技术有限公司 | β‑分泌酶特异性抑制剂的筛选方法及其筛选系统 |
| US10034861B2 (en) | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| SI3532064T1 (sl) | 2016-10-28 | 2020-10-30 | H. Lundbeck A/S | Kombinirana zdravljenja, ki obsegajo imidazopirazinone za zdravljenje psihiatričnih in/ali kognitivnih motenj |
| JP2020500841A (ja) | 2016-10-28 | 2020-01-16 | ハー・ルンドベック・アクチエゼルスカベット | イミダゾピラジノンの投与を含む併用療法 |
| WO2018132768A1 (en) * | 2017-01-13 | 2018-07-19 | Sanna Pietro P | Methods and compositions for treating hpa hyperactivity |
| CN108175855B (zh) * | 2017-05-25 | 2020-05-01 | 成都安特金生物技术有限公司 | 一种狂犬病免疫原性结合物 |
| US11634416B2 (en) | 2017-12-14 | 2023-04-25 | H. Lundbeck A/S | Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| CN117447475A (zh) | 2017-12-20 | 2024-01-26 | H.隆德贝克有限公司 | 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶 |
| CN112165956A (zh) * | 2018-04-10 | 2021-01-01 | Ac免疫有限公司 | 抗Aβ治疗性疫苗 |
| TW202003031A (zh) * | 2018-04-10 | 2020-01-16 | 瑞士商Ａｃ免疫有限公司 | 抗Ａβ治療性疫苗 |
| EP3952913A4 (en) * | 2019-04-12 | 2023-05-10 | The Johns Hopkins University | CELLS PRESENTING TOLEROGENIC ARTIFICIAL ANTIGEN |
| GB202008250D0 (en) * | 2020-06-02 | 2020-07-15 | Emergex Vaccines Holding Ltd | Diagnosis, prevention and treatment of coronavirus infection |
| CN115925987A (zh) * | 2022-02-28 | 2023-04-07 | 安域生物科技(杭州)有限公司 | 基于β-淀粉样蛋白修饰的抗原多肽及其应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US5223482A (en) | 1986-11-17 | 1993-06-29 | Scios Nova Inc. | Recombinant Alzheimer's protease inhibitory amyloid protein and method of use |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US5192688A (en) | 1988-08-15 | 1993-03-09 | Switzer Iii Robert C | Histological analysis method |
| US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| US5200339A (en) | 1990-08-17 | 1993-04-06 | Abraham Carmela R | Proteases causing abnormal degradation of amyloid β-protein precursor |
| US5780587A (en) | 1990-08-24 | 1998-07-14 | President And Fellows Of Harvard College | Compounds and methods for inhibiting β-protein filament formation and neurotoxicity |
| US5780036A (en) | 1991-08-26 | 1998-07-14 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus |
| NZ249704A (en) | 1992-02-11 | 1996-11-26 | Jackson H M Found Military Med | A two carrier immunogenic construct comprising a 70+ kd molecule conjugated to at least 1 t-dependent antigen, preparation, compositions containing the construct |
| WO1993020220A1 (en) | 1992-03-27 | 1993-10-14 | Whitehead Institute For Biomedical Research | Non-infectious hiv particles and uses therefor |
| US5851787A (en) | 1992-04-20 | 1998-12-22 | The General Hospital Corporation | Nucleic acid encoding amyloid precursor-like protein and uses thereof |
| WO1993023076A1 (en) | 1992-05-20 | 1993-11-25 | The Johns-Hopkins University | Alternative receptor therapy |
| DK100592D0 (da) | 1992-08-10 | 1992-08-10 | Mouritsen & Elsner Aps | Metode til kemisk kobling paa faste faser |
| US5958883A (en) * | 1992-09-23 | 1999-09-28 | Board Of Regents Of The University Of Washington Office Of Technology | Animal models of human amyloidoses |
| US5747323A (en) | 1992-12-31 | 1998-05-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Retroviral vectors comprising a VL30-derived psi region |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| AU707083B2 (en) | 1993-08-26 | 1999-07-01 | Bavarian Nordic Inc. | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes |
| DE69435171D1 (de) * | 1993-09-14 | 2009-01-08 | Pharmexa Inc | Pan dr-bindeproteinen zur erhöhung der immunantwort |
| AUPM411994A0 (en) | 1994-02-25 | 1994-03-24 | Deakin Research Limited | Epitopes |
| US5709995A (en) | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
| US5573916A (en) | 1994-05-19 | 1996-11-12 | Coretech, Inc. | Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier |
| IL115743A0 (en) | 1994-10-28 | 1996-01-19 | American Nat Red Cross | A mammal with cells containing a transgene and its production |
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| ES2175083T3 (es) | 1995-03-14 | 2002-11-16 | Praecis Pharm Inc | Moduladores de la agregacion de amiloides. |
| EP1741718A3 (en) | 1995-06-07 | 2007-03-28 | Sanofi Pasteur Inc. | Expression of lipoproteins |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| US5985581A (en) | 1996-07-25 | 1999-11-16 | The Mclean Hospital Corporation | Use of presenilin-1 for diagnosis of alzheimers disease |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| PT1005374E (pt) | 1997-01-22 | 2007-07-18 | Mgi Pharma Biolog Inc | Micropartículas para administração de ácido nucleico |
| AU1388899A (en) | 1997-11-11 | 1999-05-31 | Board Of Regents Of The University Of Oklahoma, The | An alzheimer-related, endothelium-derived toxic factor and methods for its use |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6787523B1 (en) * | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6913745B1 (en) * | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
| US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
| NO314086B1 (no) * | 1998-05-08 | 2003-01-27 | Gemvax As | Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til |
| JP2002521651A (ja) | 1998-07-21 | 2002-07-16 | ファーメクサ エイ／エス | 活性ポリヒドロキシポリマーでの固体表面の被覆 |
| CN1318105A (zh) | 1998-09-15 | 2001-10-17 | M&E生物技术公司 | 负调节Osteoprotegerin配体活性的方法 |
| JP2002526419A (ja) | 1998-10-05 | 2002-08-20 | ファーメクサ エイ／エス | 治療上のワクチン注射のための新規な方法 |
| WO2000027944A1 (en) † | 1998-11-06 | 2000-05-18 | Baker Hughes Incorporated | Drilling fluid systems with improved fluid loss properties |
| AU2495300A (en) | 1999-01-07 | 2000-07-24 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Lentivirus vector system |
| PT1187629E (pt) | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador |
| US6787637B1 (en) * | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| PE20010212A1 (es) | 1999-06-01 | 2001-02-22 | Neuralab Ltd | Composiciones del peptido a-beta y procesos para producir las mismas |
| AU784312B2 (en) | 1999-11-29 | 2006-03-09 | Bellus Health (International) Limited | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| CA2393763A1 (en) * | 1999-12-08 | 2001-06-14 | Mindset Biopharmaceuticals (Usa), Inc. | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| EE200200444A (et) | 2000-02-21 | 2003-12-15 | Pharmexa A/S | Meetod autoloogse beeta-amüloidvaigu in vivo mahasurumiseks, amüloidogeense polüpeptiidi analoog, seda kodeeriv nukleiinhappefragment ning kasutamineimmunogeense kompositsiooni valmistamiseks |
| CZ20022748A3 (cs) | 2000-02-21 | 2004-03-17 | Pharmexa A/S | Nová metoda regulace obsahu amyloidu |
| GB0004530D0 (en) | 2000-02-25 | 2000-04-19 | Univ Nottingham | Adjuvants |
| DE60108111T2 (de) * | 2000-05-22 | 2005-12-08 | New York University | Synthetische immunogene jedoch nicht amyloidogene peptide, die homolog zu amyloid beta sind und deren verwendung zur induktion einer immunantwort gegen amyloid beta und amyloidaggregate |
| HUP0600589A2 (en) | 2000-11-10 | 2006-11-28 | Wyeth Corp | Adjuvant combination formulations |
| US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
| JP2002273199A (ja) * | 2001-03-15 | 2002-09-24 | Idemitsu Petrochem Co Ltd | ガス状流体の抜き出し方法 |
| US6906169B2 (en) | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| MY144532A (en) * | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| US20030185845A1 (en) | 2001-11-16 | 2003-10-02 | Steen Klysner | Novel immunogenic mimetics of multimer proteins |
| WO2003059379A2 (en) | 2002-01-17 | 2003-07-24 | Pharmexa A/S | Immunogenic carcinoembryonic antigen (cea) |
| AU2003208314A1 (en) | 2002-03-11 | 2003-09-22 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| CA2493119A1 (en) | 2002-07-17 | 2004-01-22 | Mindset Biopharmaceuticals Usa Inc. | Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease |
-
2002
- 2002-08-13 MY MYPI20023002A patent/MY144532A/en unknown
- 2002-08-20 EP EP06000288A patent/EP1685847A1/en not_active Ceased
- 2002-08-20 BR BR0212047-0A patent/BR0212047A/pt not_active IP Right Cessation
- 2002-08-20 DK DK02758181T patent/DK1420815T3/da active
- 2002-08-20 WO PCT/DK2002/000547 patent/WO2003015812A2/en active Application Filing
- 2002-08-20 CA CA2457140A patent/CA2457140C/en not_active Expired - Fee Related
- 2002-08-20 AR ARP020103113A patent/AR036270A1/es active IP Right Grant
- 2002-08-20 RS YU13304A patent/RS51699B/sr unknown
- 2002-08-20 ME MEP-432/08A patent/MEP43208A/xx unknown
- 2002-08-20 SI SI200230418T patent/SI1420815T1/sl unknown
- 2002-08-20 AT AT02758181T patent/ATE334698T1/de active
- 2002-08-20 DE DE60213615.6T patent/DE60213615T3/de not_active Expired - Lifetime
- 2002-08-20 JP JP2003520770A patent/JP2004538332A/ja active Pending
- 2002-08-20 PT PT02758181T patent/PT1420815E/pt unknown
- 2002-08-20 AU AU2002325199A patent/AU2002325199B2/en not_active Ceased
- 2002-08-20 EP EP17194894.6A patent/EP3299029A1/en not_active Withdrawn
- 2002-08-20 EA EA200400332A patent/EA007533B1/ru not_active IP Right Cessation
- 2002-08-20 NZ NZ547224A patent/NZ547224A/en not_active IP Right Cessation
- 2002-08-20 US US10/223,809 patent/US20030157117A1/en not_active Abandoned
- 2002-08-20 EP EP02758181.8A patent/EP1420815B2/en not_active Expired - Lifetime
- 2002-08-20 NZ NZ530940A patent/NZ530940A/en unknown
- 2002-08-20 KR KR1020097013183A patent/KR101057488B1/ko active IP Right Grant
- 2002-08-20 PL PL369099A patent/PL215125B1/pl unknown
- 2002-08-20 CN CN200910204496.3A patent/CN101675992B/zh not_active Expired - Fee Related
- 2002-08-20 KR KR10-2004-7002557A patent/KR20040044465A/ko not_active Application Discontinuation
- 2002-08-20 KR KR1020107015762A patent/KR20100086520A/ko not_active Application Discontinuation
- 2002-08-20 MX MXPA04001467A patent/MXPA04001467A/es active IP Right Grant
- 2002-08-20 EA EA200600974A patent/EA011610B1/ru not_active IP Right Cessation
- 2002-08-20 IL IL15996402A patent/IL159964A0/xx unknown
- 2002-08-20 ES ES02758181.8T patent/ES2269749T5/es not_active Expired - Lifetime
- 2002-08-20 HU HU0400669A patent/HUP0400669A3/hu not_active Application Discontinuation
-
2004
- 2004-01-29 IS IS7133A patent/IS7133A/is unknown
- 2004-02-20 US US10/783,317 patent/US20050163744A1/en not_active Abandoned
- 2004-02-23 CO CO04015504A patent/CO5560581A2/es not_active Application Discontinuation
- 2004-03-05 HR HR20040218A patent/HRP20040218A2/hr not_active Application Discontinuation
- 2004-10-04 HK HK04107588A patent/HK1064934A1/xx not_active IP Right Cessation
-
2006
- 2006-10-26 CY CY20061101544T patent/CY1105737T1/el unknown
-
2007
- 2007-12-18 AU AU2007249087A patent/AU2007249087B2/en not_active Expired - Fee Related
- 2007-12-31 IL IL188506A patent/IL188506A/en not_active IP Right Cessation
-
2008
- 2008-12-19 US US12/339,841 patent/US8871212B2/en not_active Expired - Fee Related
-
2009
- 2009-06-12 JP JP2009141187A patent/JP5114455B2/ja not_active Expired - Fee Related
-
2010
- 2010-08-16 AU AU2010212381A patent/AU2010212381B2/en not_active Ceased
-
2012
- 2012-03-30 HR HRP20120283AA patent/HRP20120283A2/hr not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5560581A2 (es) | Vacuna de epitopo de celula t beta-amiloide analogo | |
| ES2346116T3 (es) | Epitopos artificiales de celulas t ayudadoras como estimuladores inmunes para peptidos sinteticos inmunogenos. | |
| AU2006326283B2 (en) | Therapeutic vaccine | |
| BR9306984A (pt) | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo | |
| ES2144424T5 (es) | Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige. | |
| JP2018030862A (ja) | ヘンドラ及びニパウイルスｇ糖タンパク質免疫原性組成物 | |
| PE20060816A1 (es) | Proceso para la concentracion de anticuerpos y productos terapeuticos de los mismos | |
| GT200600182A (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos | |
| NO20022531L (no) | Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer | |
| ES2702386T3 (es) | Modelos animales novedosos para evaluar compuestos farmacéuticos | |
| JP5559789B2 (ja) | アルツハイマー病の処置のための免疫治療組成物 | |
| DE68924162D1 (de) | Stressproteine und verwendungen dafür. | |
| DE69723434D1 (de) | Verfahren zur selektion und produktion von t-zell-peptide epitope und vakzine mit diese epitope | |
| ATE376559T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| SE0103754L (sv) | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid | |
| NO20004972D0 (no) | Derivater av pneumokokkiske kolinbindende proteiner | |
| BR9814473A (pt) | Imunógenos anti-retrovirais, preparação e uso | |
| ES2130121T3 (es) | Antigeno intra-acrosomico de esperma humano para uso en una vacuna anticonceptiva. | |
| TW201345928A (zh) | 組成物 | |
| AR033832A1 (es) | Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo | |
| TW201345927A (zh) | 組成物 | |
| JP2008509072A (ja) | 改良型ワクチン用のポリペプチド‐アジュバント複合体 | |
| Ding et al. | Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice | |
| Kudo et al. | IgE antibody response to mite antigen in the mouse: Suppression of an established IgE antibody response by chemically modified antigen | |
| ES2134474T3 (es) | Peptidos utilizados como agentes terapeuticos para el tratamiento de enfermedades autoinmunitarias. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |